Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Michael K. Bamat"'
Publikováno v:
Toxicology and Applied Pharmacology. 353:67-73
Uridine triacetate has been shown to be an effective antidote against mortality and toxicity caused by either overdoses or exaggerated susceptibility to the widely used anticancer agents 5-fluorouracil (5-FU) and capecitabine. However, a direct asses
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a367b6f1c2aa0cba0b9f334cc2b6f86a
https://doi.org/10.1016/j.taap.2018.06.012
https://doi.org/10.1016/j.taap.2018.06.012
Autor:
Michael K. Bamat, Thomas R. King, Thomas H. Cartwright, Bassel F. El-Rayes, Reid von Borstel, Wen Wee Ma, Marwan Fakih, James Posey, Muhammad Wasif Saif
Publikováno v:
Cancer. 123:345-356
BACKGROUND Increased susceptibility to 5-fluorouracil (5-FU)/capecitabine can lead to rapidly occurring toxicity caused by impaired clearance, dihydropyrimidine dehydrogenase deficiency, and other genetic variations in the enzymes that metabolize 5-F
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::edc2b1ab0c1e1ff4406731896c076b6b
https://doi.org/10.1002/cncr.30321
https://doi.org/10.1002/cncr.30321
Autor:
William S. Groene, Jeffrey A. Miller, James D. O'Neil, Stephen N. Mueller, Michael K. Bamat, Robert M. Lorence, M. Scot Roberts
Publikováno v:
Current Cancer Drug Targets. 7:157-167
PV701 is a naturally-attenuated, non-recombinant, oncolytic strain of Newcastle disease virus that displays preclinical intravenous (IV) efficacy. PV701 is selective at killing human cancer cells versus normal human cells based on tumor specific defe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ef2466ce0ded1af7ab27ca3b713416bc
https://doi.org/10.2174/156800907780058853
https://doi.org/10.2174/156800907780058853
Autor:
M. Scot Roberts, Sebastien J. Hotte, Hal W. Hirte, Pierre Major, James D. O'Neil, Susan R. Polawski, Michael K. Bamat, William S. Groene, Robert M. Lorence
Publikováno v:
Clinical Cancer Research. 13:977-985
Purpose: Previous phase 1 trials of i.v.-administered PV701 have shown this virus to be well-tolerated with toxicity primarily associated with the first dose. Our hypothesis, based on preclinical evidence, was that patient tolerability could be impro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::13ccc1de345e2d233ee9a6f594656c97
https://doi.org/10.1158/1078-0432.ccr-06-1817
https://doi.org/10.1158/1078-0432.ccr-06-1817
Autor:
Michael K. Bamat, William S. Groene, John C. Bell, Joanne Roach, Scott A. Laurie, M. Scot Roberts, Robert M. Lorence, James D. O'Neil, Harold L. Atkins
Publikováno v:
Clinical Cancer Research. 12:2555-2562
Purpose: In a previous phase 1 study, adverse events, especially flu-like symptoms, were observed mainly following the first i.v. bolus dose of PV701, an oncolytic Newcastle disease virus. Desensitization to adverse events of subsequent doses occurre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7c63f4bdd4ef8bf97a2c523134595354
https://doi.org/10.1158/1078-0432.ccr-05-2038
https://doi.org/10.1158/1078-0432.ccr-05-2038
Autor:
Naiyer A. Rizvi, M. Scot Roberts, Robert M. Lorence, Neal J. Meropol, Michael K. Bamat, Gary I. Cohen, Peter A. Gross, Harvey Rabin, John L. Marshall, James D. O'Neil, Daniel H. Sterman, Stuart L. Goldberg, William S. Groene, Andrew L. Pecora
Publikováno v:
Journal of Clinical Oncology. 20:2251-2266
PURPOSE: PV701, a replication-competent strain of Newcastle disease virus, causes regression of tumor xenografts after intravenous administration. This phase I study was designed to define the maximum-tolerated dose (MTD) and safety of single and mul
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bd5b7105f2137358eaa75b4681c35db4
https://doi.org/10.1200/jco.2002.08.042
https://doi.org/10.1200/jco.2002.08.042
Autor:
Thomas H. Cartwright, Wasif M. Saif, Bassel F. El-Rayes, Reid W. von Borstel, Wen Wee Ma, Marwan Fakih, Julie Vanas, Michael K. Bamat, James Posey, Thomas King
Publikováno v:
Journal of Clinical Oncology. 34:e21689-e21689
e21689Background: Uridine triacetate was approved by FDA in 2015 for adult and pediatric patients who exhibit early-onset, severe or life-threatening toxicities or who receive an overdose of 5-fluo...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5ec887398d9bc08e815517cd3245c8f6
https://doi.org/10.1200/jco.2016.34.15_suppl.e21689
https://doi.org/10.1200/jco.2016.34.15_suppl.e21689
Publikováno v:
Journal of Clinical Oncology. 34:e18232-e18232
e18232Background: Oral uridine triacetate improves survival and reduces toxicity when administered after serious overdoses of 5-fluorouracil (5-FU) in preclinical animal models and in humans. It ac...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ba79cbde34157476911891b2d3f11b86
https://doi.org/10.1200/jco.2016.34.15_suppl.e18232
https://doi.org/10.1200/jco.2016.34.15_suppl.e18232
Autor:
Bassel F. El-Rayes, Wen Wee Ma, James Posey, Thomas King, Michael K. Bamat, Reid W. von Borstel, Marwan Fakih, Thomas H. Cartwright
Publikováno v:
Journal of Clinical Oncology. 34:e21612-e21612
e21612Background: Uridine triacetate was approved by FDA in 2015 for adult and pediatric patients who receive an overdose of 5-fluorouracil or capecitabine or who exhibit early-onset, severe or lif...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7e7f054be6426052fb2a84ee0c7480e1
https://doi.org/10.1200/jco.2016.34.15_suppl.e21612
https://doi.org/10.1200/jco.2016.34.15_suppl.e21612
Autor:
Thomas H. Cartwright, Bassel F. El-Rayes, Wasif M. Saif, Marwan Fakih, James Posey, Michael K. Bamat, Reid W. von Borstel, Wen Wee Ma
Publikováno v:
Journal of Clinical Oncology. 34:655-655
655 Background: Life-threatening or lethal 5-FU toxicity occurs due to infusion pump/reservoir errors and 5-FU dosage miscalculations. Additionally, DPD-deficient patients often experience serious or lethal toxicity. Regardless of DPD status, some pa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::62c10d651cf25d3683cbcf38cd0cb84e
https://doi.org/10.1200/jco.2016.34.4_suppl.655
https://doi.org/10.1200/jco.2016.34.4_suppl.655